PDCD1 and neoplasm: In the absence of observed tumor suppression by PD-1 or anti-PD-L1 against pancreatic cancer in Panc 02 tumor model, synergistic treatment with 2-BP rendered tumors significantly sensitive to immune checkpoint blockade (ICB).